

State of Oklahoma

Oklahoma Health Care Authority

Prior Authorization Form: Makena® (17-hydroxyprogesterone caproate), Crinone®

(progesterone (ger), and Endometrin	(progeste	rone vaginai insert)	
Member Name:	SoonerCare ID #:		Date of Birth:	
Pharmacy NPI:	Pharmacy Phone:		Pharmacy Fax:	
Pharmacy Name:			Pharmacist Name:	
Prescriber NPI #:	Prescriber Name:			
Specialty:	Prescriber Phone:		Prescriber Fax:	
Medication Requested:				
Drug Name:	Strength:	Dosage:	Refills:	
Drug Name: Fill Quar	ntity: Day Supply:	_		
If requesting Makena®: Please note	only exact amount of mL requ	ired will be app	roved. If the 5ml vial will be used, please	
provide NDC's for both the 1ml vial				
		Auto-Injector: NDC:		
If requesting Endometrin® or Crinon				
.,, 0				
Makana® /17 Hudrowynagostoron	Criteria			
Makena® (17-Hydroxyprogesterone		m daliwam//CDTD) prior to 27 weeks gostation, and	
1. Documented history of previous		ii delivery (SPTD) prior to 37 weeks gestation; <u>and</u>	
2. Current singleton pregnancy; and 2. Containing large between 16 weeks 0 days and 26 weeks 6 days goetation				
 Gestational age between 16 weeks, 0 days and 26 weeks, 6 days gestation. Authorizations will be for once a week administration by a healthcare professional through 36 weeks, 6 days gestation. 				
	•	•	, ,	
Endometrin® (Progesterone Vagina		erone Vaginal G	el) Approval Criteria:	
1. Current singleton pregnancy; and				
•	/			
 Cervical length of ≤ 20mm; and 				
. Gestational age between 20 weeks, 0 days and 26 weeks, 6 days of gestation; and				
5. For those requesting Crinone®: A patient-specific, clinically significant reason why the member cannot use Endometrin®				
6. Authorizations will be given for treatment through 36 weeks, 6 days of gestation.				
7. Endometrin® and Crinone® will	<u>not</u> be covered for use with ass	isted reproducti	ve technology (ART) for female infertility.	
	Clinical Inform	nation		
1. Does member have a history of	previous singleton spontaneou	s preterm delive	ry (SPTD): Yes No	
2. Date and gestational age of prev	vious singleton spontaneous pr	eterm delivery (S	SPTD):	
3. Current singleton pregnancy:	Vas No Data o	f I Iltracound:		
4. Gestational age of current pregr		Date:		
For Makena® Auto-Injector:	-l ® At l.a.;t ll.a.;		laborano munefonsia me 12 Mare. No	
1. Will the initial dose using the Makena® Auto-Injector be administered by a healthcare professional? Yes No 2. Has the member/caregiver been trained by a healthcare professional on subcutaneous administration and storage of				
	•	ssional on subcut	caneous administration and storage of	
Makena® Auto-Injector? Yes	· · · · · · · · · · · · · · · · · · ·			
For Endometrin® or Crinone®: Mem				
Additional Information or patient-sp	ecific, clinically significant reas	on for use of Crii	none [®] in place of Endometrin [®] :	
I certify that the indicated treatment is	medically necessary and all inform	ation is true and o	correct to the best of my knowledge.	
Prescriber/Pharmacist Signature: Date:				
			nt records.) Please do not send in chart notes.	
Specific information/documentation will be			I will result in processing delays. CONFIDENTIALITY NOTICE	
		į.	AANLIATIVIALIT INGALIE	

University of Oklahoma College of Pharmacy **Pharmacy Management Consultants** Product Based Prior Authorization Unit Fax: 1-800-224-4014

Phone: 1-800-522-0114 Option 4

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.